Articles tagged with Chemotherapy
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A Cleveland Clinic study has detected significant changes in brain activity patterns of patients receiving chemotherapy, supporting the existence of 'chemobrain'. Women showed higher amplitude brain activity after physical and cognitive tasks during treatment.
A clinical trial found that duloxetine reduced painful tingling feelings caused by chemotherapy in 59 percent of patients. The study suggests that this antidepressant may be an effective treatment for chemotherapy-induced peripheral neuropathy pain.
A new study led by University of Rochester Medical Center researcher Barbara L. Asselin shows that giving a cardio-protective drug during cancer treatment may prevent damage to the hearts of childhood leukemia survivors. The study found that the drug Zinecard significantly reduced heart problems and damage in patients who received it.
A new frontline treatment regimen combining carfilzomib, lenalidomide, and low-dose dexamethasone resulted in complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma. The study found that the regimen was well-tolerated, with improved responses as treatment continued.
A new breast cancer treatment, trastuzumab emtansine (T-DM1), has shown significant improvements over standard therapy in keeping advanced tumors from progressing, with fewer and less harsh side effects.
A study by Weizmann Institute scientists reveals that leukemia recurrence is often caused by 'cancer stem cells' that divide slowly, evading chemotherapy drugs. These cells can give rise to new rapidly-dividing cancer cells, making them a key target for new treatment approaches.
A new study shows that Breast MRI provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination. MRI size measurements were superior to clinical examination at all time points, predicting both complete tumor response and residual cancer burden.
A new study suggests that a protein called heat shock factor-1 (HSF-1) is involved in chemotherapy-related heart damage. Researchers propose targeting HSF-1 in the heart as a potential therapy to prevent cardiac damage, potentially leading to improved outcomes for cancer patients undergoing chemotherapy.
A new study has shown that giving a daily low-dose of the chemotherapy drug carboplatin at the same time as radiotherapy significantly prolongs survival in elderly patients with lung cancer. Patients who received combined chemoradiotherapy were nearly a third less likely to die than those given radiotherapy alone.
A new treatment regimen, accelerated MVAC, has been shown to provide comparable benefits to standard chemotherapy without the same toxicity. This accelerated schedule of six weeks has improved response rates and tolerability for patients with muscle-invasive bladder cancer.
A recent study suggests a positive correlation between tumor size and chemotherapy efficacy in surgically resected patients with node-negative non-small cell lung cancer. The study found no clear threshold for tumor size that correlated with a benefit from chemotherapy.
A recent study found that 54% of patients with stage two and three rectal cancer did not receive treatment consistent with guidelines. The study, published in Clinical Oncology, also showed significant regional variation in treatment patterns across Alberta.
Researchers found that administering cyclophosphamide before bone tumors took root fertilized the bone marrow, enabling cancer cells to seed and grow. The study reversed this effect by inhibiting CCL2, suggesting a potential approach for preventing metastasis in certain cancers.
Pazopanib nearly tripled progression-free survival in patients with metastatic soft-tissue sarcoma whose disease has progressed following standard chemotherapy. The median follow-up was 15 months, and common side effects included fatigue, diarrhoea, and hypertension.
Researchers developed gene expression signatures to predict breast cancer patient responses to chemotherapy. The signatures, based on TOP2A and β-tubulin, accurately predicted complete response rates and combined indices improved accuracy.
Researchers at Fred Hutchinson Cancer Center have successfully transplanted gene-modified blood stem cells into brain cancer patients to protect their bone marrow against chemotherapy's toxic effects. The study showed that two patients survived longer than predicted, with one remaining alive for over three years.
Researchers have developed a potent new drug called Lys05 that kills tumor cells in mouse models by clogging their recycling system. This approach has shown promise as a single-agent anti-tumor therapy with minimal toxicity to healthy cells.
Researchers identified a group of patients with high immune response gene expression who are more likely to have their tumors completely eradicated by pre-operative chemotherapy. Patients with HER2-positive and ER-negative/HER2-negative subtypes showed better treatment outcomes.
Researchers at Moffitt Cancer Center found that breast cancer survivors who underwent chemotherapy and/or radiation therapy performed worse on cognitive tests than those who did not have cancer. The study's findings suggest long-term cognitive effects of these therapies need further investigation.
A new analysis of the TORCH trial found that erlotinib is most effective in patients with EGFR mutations, while those with wild-type tumors should receive standard chemotherapy first. The study confirms the importance of biomarker testing to guide treatment decisions.
Researchers analyzed data from 4,168 Medicare beneficiaries with advanced non-small cell lung cancer aged 65 or older. They found no significant difference in overall survival between those treated with bevacizumab and those receiving standard chemotherapy alone. The study's findings suggest that bevacizumab should not be considered th...
Researchers at Case Western Reserve University have developed a magnetic nanochain delivery system that explodes chemotherapy drugs inside tumors, killing cancer cells more efficiently. The technology reduced tumor growth by up to 90% and increased survival rates in rats with triple-negative breast cancer.
A study by Dana-Farber Cancer Institute researchers found that adding bevacizumab to standard chemotherapy for non-small cell lung cancer in patients over 65 did not significantly increase survival rates. The treatment approach was previously approved by the FDA but failed to show substantial benefits.
Researchers used live microscopy to observe how cancer cells react to chemotherapy in different tumor microenvironments. Selective inhibition of certain enzymes and immune signaling molecules made breast tumors more responsive to doxorubicin, a widely used chemotherapeutic agent.
A DNA repair pathway-focused score has been developed to predict chemotherapy response in ovarian cancer patients. The score is positively correlated with complete response rate, recurrence-free survival, and progression-free survival, and outperforms other clinical factors in predicting overall survival.
Researchers from the University of Hull have identified a family of proteins associated with chemotherapy resistance in breast cancer patients. The 14-3-3 protein family was found to be twice as prevalent in resistant patients, suggesting its potential use as a predictive test for clinical decision-making.
Combining antiangiogenesis drugs with smaller nanomedicines may enhance treatment effectiveness for certain cancers. Vascular normalization temporarily decreases tumor blood vessel diameter, improving drug penetration of smaller particles but not larger molecules.
A new fractionated dosing regimen of gemtuzumab ozogamicin significantly improves event-free survival and overall survival for patients with acute myeloid leukaemia. The regimen reduces toxicity while delivering a high cumulative dose of the drug.
A study by Dr. Andreas Engert and colleagues found that six cycles of BEACOPPescalated chemotherapy followed by radiotherapy are more effective in treating advanced Hodgkin's lymphoma with fewer treatment-related events. This approach also reduces toxicity compared to the standard eight-cycle regimen.
A study found that adding cetuximab to a regimen of drugs after stage III colon cancer surgery did not improve disease-free survival. The trial tested the combination in patients with resected stage III wild-type KRAS colon cancer and showed no benefit.
A genetic marker in blood can determine if a patient with ovarian cancer will benefit from chemotherapy after surgery. This discovery offers hope to patients diagnosed at stage III of the disease, who have a poor prognosis without effective treatment.
A harmless human virus, RT3D, has shown promise in boosting the effects of chemotherapy drugs in advanced head and neck cancer patients. In a Phase I/II trial, approximately one-third of patients experienced tumor shrinkage and disease stabilization.
A Mayo Clinic study found that the dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice. Combining GLA with chemotherapy drug gemcitabine significantly inhibited tumor growth.
Researchers found that activating a cholesterol pathway may enhance chemotherapy's effectiveness against pancreatic cancer. The study used a cholesterol derivative to block the Hedgehog pathway, which is linked to both cancer and heart disease.
A study by UCLA's Jonsson Comprehensive Cancer Center found that early Positron Emission Tomography (PET) response after neoadjuvant chemotherapy is associated with increased survival in patients with soft tissue sarcomas. Patients who showed a significant PET response had significantly longer survival rates compared to those who did not.
Researchers have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models. The results show that imipramine blue stops tumor invasion and enhances the efficacy of chemotherapy.
Researchers developed a novel compound that stops cancer cells from invading healthy brain tissue, improving treatment outcomes in animal models. The compound, imipramine blue, is combined with chemotherapy to enhance its effectiveness.
Researchers at the University of Alberta discovered that some breast cancer tumors with weak 'survival' systems responded better to taxane chemotherapy than those with strong survival systems. This finding could lead to new strategies for identifying patients who may not respond to this common treatment.
Researchers aim to create targeted compounds that selectively attack cancerous cells by zeroing-in on pollutants produced by tumors' characteristic metabolism. This approach seeks to minimize side effects associated with conventional chemotherapy.
Researchers found a strong correlation between genetic variation and chemotherapy side effects, enabling personalized treatment approaches. This study aims to tailor chemotherapy regimens to individual patients' genetic profiles.
A new genomic test has been shown to help doctors identify breast cancer patients who do not need adjuvant chemotherapy, reducing side effects and improving quality of life. The study found that patients classified as low risk by the test had a higher distant disease-free survival rate compared to those classified as high risk.
Detecting circulating tumour cells in blood can provide information about breast cancer survival and help target treatment. Patients with high CTC counts have a higher risk of recurrence and death, while CTC detection may also become a target for future therapy.
Scientists at Fred Hutchinson Cancer Research Center and TGen have discovered a way to break down the biological barrier surrounding pancreatic cancer tumors, allowing chemotherapy drugs to reach the cancerous tissue. This breakthrough could lead to improved survival rates for patients with pancreatic cancer.
Researchers have found that a new drug called plerixafor can help drive leukemia cells out of the bone marrow and into the bloodstream, making them more vulnerable to chemotherapy. In a clinical trial, 46% of patients with acute myeloid leukemia achieved complete remission after treatment.
A recent study published in Journal of Thoracic Oncology suggests that CYFRA21-1 levels can reliably indicate patient response to chemotherapy for non-small cell lung cancer (NSCLC). Higher baseline concentrations were linked to poorer overall and failure-free survival. Further research is needed to confirm these findings.
Scientists have successfully mapped tens of thousands of molecular signaling events involved in DNA damage repair, shedding light on how cells communicate when their DNA is broken. This research will help develop new drugs with fewer side effects and better protect healthy cells during cancer treatment.
A recent study found that Asian breast cancer patients suffer from memory loss, decision-making difficulties, and speech problems after chemotherapy treatment. To cope with these changes, many turned to mind stimulation activities such as mahjong and qi gong.
A team of researchers at Duke University has determined the structure of a concentrative nucleoside transporter, which works by moving nucleosides from outside to inside of cells. This discovery may lead to more effective drugs with fewer effects on healthy tissue.
Researchers found that telomeres send out a molecular SOS signal when cells take too long to divide, leading to the activation of DNA damage pathways and cell death. This discovery has implications for cancer chemotherapy, suggesting ways to make therapy more potent by combining mitotic inhibitors with other drugs.
Cancer cells use an 'emergency brake' to protect themselves from chemotherapy drugs, which can be rendered inoperative by targeting a specific enzyme pathway. The study identifies PARP inhibition as a promising therapeutic approach to improve chemotherapy effectiveness.
Researchers used X-rays to decipher how certain natural antibiotics defy chemical rules, unlocking a mechanism that could enable scientists to synthesize many important chemicals currently found only in nature. The discovery has broad implications, as the six-membered ring is a common structural feature found in hundreds of drug molecu...
Researchers found that a protein called FOXM1 protects cancer cells from chemotherapy and radiation-induced cell death. Combining standard drugs with proteasome inhibitors may improve treatment effectiveness.
A study by UNC Health Care researchers found that a supercharged version of the protective protein focal adhesion kinase (FAK) can reduce heart attack damage by 50% in mice. The enhanced protein, called SuperFAK, was engineered to activate stronger survival signals and deactivate at the right time, reducing permanent heart damage.
A new study by researchers at H. Lee Moffitt Cancer Center has found that the XL888 inhibitor can prevent resistance to chemotherapy drug vemurafenib in melanoma patients, leading to induced apoptosis response and tumor regression. The study suggests a novel approach to managing drug resistance using broadly targeted strategies.
A study published in the Journal of Clinical Oncology found that women who underwent chemotherapy with the CMF regimen between 1976 and 1995 scored slightly lower on cognitive tests compared to those without a history of cancer. The differences were subtle but statistically significant, affecting word learning, memory, and information ...
Researchers found that Aurora-A phosphorylates p73, preventing it from detecting DNA damage and triggering programmed cell death. This allows cancer cells to resist chemotherapy and radiation treatment, making them harder to treat.
Researchers have discovered that adding hydroxychloroquine to various cancer therapies can enhance their effectiveness in treating treatment-resistant cancers. By blocking autophagy, a process by which cells recycle damaged proteins, the combination of chemotherapy and HCQ can lead to improved outcomes for patients.
A new strategy combining carbon nanoparticles with chemotherapy and radiation therapy shows significant potential in treating head-and-neck cancers. The treatment uses nanoparticles to encapsulate chemotherapeutic drugs, delivering them directly to cancer cells.
Researchers have gained a better understanding of two key proteins that control cell division, which could lead to the development of new drugs to stop cancerous cells multiplying. This discovery could also help optimise personalised chemotherapy treatments and limit side effects associated with some chemotherapy drugs.
Researchers found that combining chemotherapy with antibody treatment against intracellular antigens delays tumor growth and prolongs survival. The approach uses chemotherapy to release antigens from cancer cells, allowing antibodies to effectively target them.